A new trading day began on Tuesday, with Moderna Inc (NASDAQ: MRNA) stock price down -1.83% from the previous day of trading, before settling in for the closing price of $26.74. MRNA’s price has ranged from $23.15 to $58.96 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -42.94%. Meanwhile, its annual earnings per share averaged -3.16%. With a float of $344.88 million, this company’s outstanding shares have now reached $389.00 million.
The extent of productivity of a business whose workforce counts for 5800 workers is very important to gauge.
Moderna Inc (MRNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 11.70%, while institutional ownership is 73.41%. The most recent insider transaction that took place on Jun 11 ’25, was worth 8,736. In this transaction Director of this company sold 312 shares at a rate of $28.00, taking the stock ownership to the 580 shares. Before that another transaction happened on Jun 11 ’25, when Company’s Director proposed sale 312 for $28.00, making the entire transaction worth $8,736.
Moderna Inc (MRNA) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.03 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.26% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Here are Moderna Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.52, a number that is poised to hit -2.08 in the next quarter and is forecasted to reach -7.46 in one year’s time.
